CTI Molecular Imaging, Inc. Reports Financial Results for the
Fourth Quarter of Fiscal 2004 Net Revenues of $130 Million and EPS
of $0.20 Exceed Prior Guidance KNOXVILLE, Tenn., Nov. 16
/PRNewswire-FirstCall/ -- CTI Molecular Imaging, Inc.
(NASDAQ:CTMI), a leading provider of positron emission tomography
(PET) equipment, molecular biomarkers and related services, today
announced financial results for its fourth quarter ended September
30, 2004. Net revenues for the fourth quarter were $129.6 million,
a 7.5% increase from net revenues of $120.6 million for the same
period last year. Net income was $9.4 million, or $0.20 per share
on a fully-diluted basis, compared to $5.2 million, or $0.11 per
share, in the prior fiscal year's fourth quarter. For the full
year, net revenues were $401.7 million, a 10.9% increase from net
revenues of $362.3 million in 2003. Net income for 2004 was $18.6
million, or $0.40 per share on a fully-diluted basis, versus $20.6
million, or $0.44 per share, in 2003. "Fiscal 2004 concluded with
improved performance across our business units. Our revenue and
earnings per share results for the fourth quarter were well ahead
of our plan and guidance. This growth was accomplished while
maintaining a disciplined cost structure, with gross margins of 39%
and operating margins of over 20%," said Ronald Nutt, Ph.D.,
President and Chief Executive Officer. During the fourth quarter,
on a consolidated basis CTI Molecular Imaging sold 48 scanners.
"The level of demand in the North American market for PET and
PET/CT equipment has shown some improvement, while the
international market continues to experience solid growth. We enter
fiscal 2005 with good visibility on the pipeline of transactions
for the year. The sales force realignment with Siemens has
contributed to our improved outlook, as our closer cooperation has
yielded better market intelligence, new incremental scanner sales
opportunities, greater cross-sales potential and a more efficient
cost structure. We anticipate that this new sales structure will
build momentum as the year progresses," continued Dr. Nutt. The CTI
Solutions segment experienced significantly improved financial
performance and achieved positive income from operations for the
first time in two years. Contributing to this improvement were
strong sales of FDG during the quarter. For the fourth quarter,
sales of FDG doses increased 45% over the prior year's quarter and
7% sequentially, partially offset by a 3% sequential decline in
average price. "The benefits of the sales agency agreement with
Siemens were evident in our financial results, as the direct
distribution efforts were no longer a drag on the profitability of
CTI Solutions," added Dr. Nutt. The financial results of the
company for the fourth quarter were adversely impacted by an
arbitration settlement of a dispute with a former supplier. The
arbitrator ruled in favor of the former supplier, and as a result,
CTI took a one-time, pretax charge of $4.2 million in its Detector
Materials business unit during the fourth quarter for settlement
payments owed to the former supplier. On November 3, 2004 the
Centers for Medicare and Medicaid Services (CMS) announced the
final 2005 Medicare ambulatory payment classification (APC) rates
for PET procedures. CMS has adjusted the combined payments for the
use of a PET scanner and the administration of FDG to $1,371.11 for
2005, from the level of $1,774.48 in 2004. "We believe that the
reduction of reimbursement levels for PET is consistent with the
above-mentioned continued growth in PET utilization and expect that
it will not have a significant adverse effect on the level of
demand for scanners in the U.S. in 2005. These rates directly apply
only to the hospital-based imaging center market which represents
about 10% to 15% of the PET market in the U.S. In finalizing our
budget, we believe that we have taken these reimbursement changes
into account in setting our expectations for domestic scanner
demand in 2005," continued Dr. Nutt. Segment Information: Three
Months Ended Twelve Months Ended September 30, September 30, (in
thousands) 2004 2003 2004 2003 Revenues, gross: CPS $79,627 $96,910
$266,864 $247,739 Detector Materials 4,468 12,874 47,095 55,164 CTI
Solutions 63,224 66,197 196,234 192,819 Total $147,319 $175,981
$510,193 $495,722 Revenue eliminations: CPS $(12,764) $(41,712)
$(57,258) $(75,726) Detector Materials (4,216) (12,487) (46,436)
(52,312) CTI Solutions (765) (1,221) (4,751) (5,395) Total
$(17,745) $(55,420) $(108,445) $(133,433) Revenues, net: CPS
$66,863 $55,198 $209,606 $172,013 Detector Materials 252 387 659
2,852 CTI Solutions 62,459 64,976 191,483 187,424 Total $129,574
$120,561 $401,748 $362,289 Income (loss) from operations: CPS
$23,124 $18,715 $50,623 $47,984 Detector Materials (2,376) 8,574
19,774 25,889 CTI Solutions 973 (3,773) (11,344) (9,676) Corporate
4,963 (5,080) (1,049) (6,476) Total $26,684 $18,436 $58,004 $57,721
Shipments and Backlog: The company sold 48 scanners during the
fourth quarter and 152 scanners for the fiscal year. Backlog on a
consolidated basis at September 30, 2004 was $139 million, which
includes orders for PET/CT scanners, cyclotrons and service and
maintenance contracts, and excludes orders placed for FDG doses.
Financial Outlook: "With the encouraging results from the fourth
quarter and the improved visibility for scanner demand, we are
optimistic about our scanner sales forecast for fiscal 2005. We now
expect scanner sales of approximately 175 units, reflecting a
stable U.S. market and escalating growth in international
shipments. Net revenues for the year are anticipated to be in the
range of approximately $420 million to $430 million and earnings
per share should be approximately $0.50 to $0.52. For the first
quarter of 2005, which traditionally is our slowest volume quarter,
we expect revenue of approximately $90 million and earnings per
share in the range of $0.03 to $0.05," said Dr. Nutt. Conference
Call Information: The dial-in number for today's earnings call at
9:00 a.m. EST is (706) 643-3432. A replay of the call will be
available for one week until November 23, 2004. To hear this
replay, please dial (800) 642-1687 and enter the reservation number
1430567. A simultaneous webcast of the call will be accessible via
the internet at http://www.ctimi.com/ under the Investor Relations
section. A replay of the webcast will also be archived on this
site. About CTI Molecular Imaging: CTI Molecular Imaging, Inc. is a
leading supplier of products and services for positron emission
tomography (PET), a diagnostic imaging technology used in the
detection and treatment of cancer, neurological disorders and
cardiac disease. Additional information is available at:
http://www.ctimi.com/ . About PET and PET/CT: PET images the
biology of diseases at the molecular level, often before anatomic
changes are visible or, in some cases, before symptoms appear.
Diseases are biological processes and it is these processes that
PET examines. PET/CT is an imaging technology that combines the
biological examination of patients by PET with the CT images of the
body's structural detail. PET/CT technology improves the diagnostic
accuracy and treatment management of patients by providing
surgeons, radiation oncologists and other physicians with precise
anatomical landmarks associated with the disease condition as
determined by PET. PET's whole-body imaging capability helps
physicians improve their ability to detect and determine the
location, extent and stage of cancer, neurological disorders and
cardiac disease. By improving diagnosis, PET scans aid physicians
in selecting better courses of treatment, as well as assessing
whether treatment is effective or should be changed. Recent
published clinical trials have shown that in a wide array of
cancers, the use of PET has caused the treatment to be changed for
15 to 50% of patients, depending on the specific clinical question.
In addition, PET and PET/CT provide both the patient and their
physician with a degree of certainty that is often unavailable
through other imaging methods. Certain matters discussed in this
press release and the related conference call constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements, which may be identified by words such as "believe,"
"expect," "anticipate," "intend," "estimate" or similar
expressions, include statements regarding CTI's financial outlook
for 2005, the anticipated financial and operational improvements
resulting from the new agency agreement with Siemens, future demand
for scanners, the impact of reduced reimbursement levels for PET,
future pricing trends and any other statements that necessarily
depend on future events. Forward-looking statements involve a
number of risks and uncertainties and there can be no assurance
that any forward-looking statements will prove to be accurate.
Important factors that could cause actual results to differ
materially from those anticipated in the forward- looking
statements include: competition; uncertainties and potential
difficulties regarding the implementation of the new agency
agreement with Siemens; the seasonality of capital equipment sales;
the availability and amount of third-party payor reimbursement for
PET procedures; Siemens' option to purchase a majority interest in
CPS, CTI's subsidiary that develops and manufactures PET scanners;
market adoption of and demand for PET products in general and CTI's
products and services in particular; the timing of orders from
distribution partners and customers; legislative and regulatory
developments; the timing of research and development and marketing
expenses; relationships with suppliers and distributors; pricing;
customer demand for financing services; and general economic
conditions, such as interest rates. CTI undertakes no obligation to
update or revise any forward-looking statements. Further
information regarding risks, uncertainties and other factors that
could adversely affect CTI or cause actual results to differ
materially from those anticipated in forward-looking statements are
included in CTI's Annual Report on Form 10-K for the fiscal year
ended September 30, 2003 and Quarterly Report on Form 10-Q for the
quarter ended June 30, 2004. CTI Molecular Imaging, Inc
Consolidated Balance Sheets September 30, September 30, (in
thousands) 2004 2003 ASSETS Current assets: Cash and cash
equivalents $36,381 $49,978 Accounts receivable -- trade, net
65,707 72,240 Accounts receivable -- related party, net (1) 34,470
42,430 Inventories 92,219 70,852 Deferred tax asset 13,474 17,751
Prepaid expenses and other current assets 8,345 7,691 Total current
assets 250,596 260,942 Property and equipment, net 133,074 107,293
Goodwill 46,629 25,040 Other assets 34,915 31,773 Total assets
$465,214 $425,048 LIABILITIES AND SHAREHOLDERS' EQUITY Current
liabilities: Trade accounts payable $33,012 $46,507 Current
maturities of long-term debt and capital lease obligations 4,289
5,501 Accrued liabilities 22,059 25,854 Customer advances 9,801
6,863 Income taxes payable 4,472 3,724 Total current liabilities
73,633 88,449 Other long-term liabilities 4,447 2,332 Deferred tax
liability 5,013 8,999 Long-term debt and capital lease obligations
12,856 18,688 Total liabilities 95,949 118,468 Minority interest
62,213 46,727 Shareholders' equity 307,052 259,853 Total
liabilities and shareholders' equity $465,214 $425,048 (1)
Represent receivables from Siemens Medical Solutions USA, Inc. CTI
Molecular Imaging, Inc. Consolidated Statements of Operations Three
Months Ended Twelve Months Ended September 30, September 30, 2004
2003 2004 2003 (In thousands, except share and per share data)
Revenues $129,574 $120,561 $401,748 $362,289 Cost of revenues
79,316 75,941 242,804 219,127 Gross margin 50,258 44,620 158,944
143,162 Operating expenses: Selling, general and administrative
expenses 15,789 15,812 65,047 52,221 Research and development
expenses 7,038 8,481 33,363 29,931 Write-off of in process research
and development - 1,380 - 1,380 Stock-based compensation expense
747 511 2,530 1,909 Total operating expenses 23,574 26,184 100,940
85,441 Income from operations 26,684 18,436 58,004 57,721 Interest
expense, net 136 298 1,375 804 Other income (355) (749) (585)
(1,968) Income before income taxes and minority interest 26,903
18,887 57,214 58,885 Provision for income taxes 9,994 7,706 21,918
22,935 Income before minority interest 16,909 11,181 35,296 35,950
Amount applicable to minority interest, net of taxes 7,517 5,996
16,676 15,387 Net income $9,392 $5,185 $18,620 $20,563 Earnings per
share Basic $0.21 $0.12 $0.42 $0.47 Diluted $0.20 $0.11 $0.40 $0.44
Weighted average shares Basic 44,925,131 44,232,893 44,673,893
43,351,390 Diluted 47,767,417 46,236,820 46,774,504 46,457,355
DATASOURCE: CTI Molecular Imaging, Inc. CONTACT: David N. Gill or
Michael A. Lawless of CTI Molecular Imaging, Inc., +1-865-218-2000
Web site: http://www.ctimi.com/
Copyright
Cti Molecular Imaging (NASDAQ:CTMI)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Cti Molecular Imaging (NASDAQ:CTMI)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024